Evidence map›Paper›PMID 34303373›Full record

ArticleArthritis research & therapy2021

Differences in oxylipin profile in psoriasis versus psoriatic arthritis.

Roxana Coras, Arthur Kavanaugh, Angela Kluzniak, Dustina Holt, Amy Weilgosz, Armando Aaron, Oswald Quehenberger, Christopher Ritchlin, Monica Guma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Eicosanoid profiles in an arthritis model: Effects of a soluble epoxide hydrolase inhibitor.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Lipidomic Profiling in Synovial Tissue.Frontiers in medicine · 2022
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Roxana CorasDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA. rcoras@health.ucsd.edu.ORCID 0000-0001-9547-218X
Arthur KavanaughDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Angela KluzniakDepartment of Medicine, University of Rochester, Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Dustina HoltDepartment of Medicine, University of Rochester, Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Amy WeilgoszDepartment of Medicine, University of Rochester, Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Armando AaronDepartment of Pharmacology, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Oswald QuehenbergerDepartment of Pharmacology, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Christopher RitchlinDepartment of Medicine, University of Rochester, Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Monica GumaDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
University of Rochester Medical Center · USUniversity of California San Diego · USUniversitat Autònoma de Barcelona · ES

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILES Frome WILKINSON · 2003 to 2026
$40.4M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Targeting hexokinase-2 in rheumatoid arthritisR01AR073324 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUMA, MONICA · 2018 to 2022
$2.4M
NIAMS NIH HHS R01 AR073324NIAMS NIH HHS T32 AR064194NIH HHS 1R01AR0690000-01NIH HHS P30DK063491NIH HHS T32AR064194
6 · The paper itself

Abstract

backgroundOxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers.

methodsConsecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1.

resultsTwenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without.

conclusionsThe AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients.

Indexed as

Arthritis, PsoriaticPsoriasisArachidonic AcidsFemaleHumansMaleMiddle AgedOxylipinsSeverity of Illness Index5-oxo-eicosatetraenoic acidArachidonic AcidsOxylipinsEnthesitisOxylipinsPsoriasisPsoriatic arthritisSkin disease

Identifiers

PMID34303373
PMCPMC8310583
OpenAlexW3184659538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.